IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
05 December 2024 - 12:00AM
Business Wire
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”)
(NASDAQ: IPA), an AI-driven biotherapeutic research and technology
company, today announced it will be presenting at The Benchmark
Company’s 13th Annual Discovery One-on-One Investor Conference to
be held Wednesday, December 11th, 2024, at the New York Athletic
Club in New York City.
The conference offers emerging growth, and dynamic publicly
traded companies access to institutional and individual investors
in a unique one-on-one format. During the event, Dr. Jennifer Bath,
President and CEO, will be participating in one-on-one meetings
with investors and analysts throughout the day. To schedule a
one-on-one meeting with Dr. Jennifer Bath, please first register
here for the conference. Once you are registered, you'll gain
access to the platform to submit your meeting request.
About The Benchmark Company
The Benchmark Company is an institutionally focused, research
driven, sales trading and investment banking firm. We were founded
in 1988 and are headquartered in New York City. Our focus is on
fostering the long-term success of our corporate clients through
raising capital, providing strategic advisory services, generating
insightful research, and developing institutional sponsorship by
leveraging the firm’s sales, trading, and equity research
capabilities. https://www.benchmarkcompany.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that
leverages multi-omics modeling and complex artificial intelligence
through a series of proprietary and patented technologies. The
Company owns an integrated end-to-end suite of capabilities to
support the development of therapeutic antibodies and is known for
solving very complex industry challenges. IPA has several
subsidiaries in North America and Europe including entities such as
Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies
(Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V.
(collectively, the “IPA Family”).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241204494793/en/
Investor Relations Contact
investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Dec 2024 to Jan 2025
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Jan 2024 to Jan 2025